Valve-in-Valve: High or Low Implantation for Better Outcomes?

Original Title: Transcatheter Replacement of Failed Bioprosthetic Valve. Large Multicenter Assessment of the Effect of Implantation Depth on Hemodynamics after Aortic Valve-in Valve. Reference: Matheus Simonato, et al. Circ. Cardiovasc. Interv 2016;9:e003651   Courtesy of Dr. Carlos Fava.   At present, most patients undergoing surgical valve replacement receive a bioprosthetic valve, which lasts from 10 to<a href="https://solaci.org/en/2016/07/12/valve-in-valve-high-or-low-implantation-for-better-outcomes/" title="Read more" >...</a>

Medtronic’s New CoreValve Evolut R for TAVR

Original Title: Treatment of Symptomatic Severe Aortic Stenosis with a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. Reference: Ganesh Manoharan et al. J Am Coll Cardiol Intv. 2015; 8(10):1359-1367.   Courtesy of Dr. Agustín Vecchia. Despite the rapid growth and evolution of transcatheter aortic valve replacement devices (TAVR), vascular access complications, paravalvular leak, stroke<a href="https://solaci.org/en/2016/07/08/medtronics-new-corevalve-evolut-r-for-tavr/" title="Read more" >...</a>

Percutaneous mitral valve replacement: First steps

Original Title: Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. Reference: Eleid MF et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1161-74.   Courtesy of Dr. Agustín Vecchia.   Transfemoral percutaneous transvenous mitral valve implantation is a promising technique and, despite the fact that no devices<a href="https://solaci.org/en/2016/06/16/percutaneous-mitral-valve-replacement-first-steps/" title="Read more" >...</a>

Extreme Valve Calcification in TAVI might compromise technical success

Original Title: Ballon-Expandable Trancatheter Aortic valve Replacement in Patients whit Extreme Aortic Valve Calcification. Reference: Yigal Abramowitz, et al. Catetherization and Cardiovascular Intervention 2016;87:117-1179.   Courtesy of Dr. Carlos Fava.   Transcatheter aortic valve replacement (TAVI) emerged as a valid option to treat high risk inoperable patients. A group of these patients presents extreme valve<a href="https://solaci.org/en/2016/06/16/extreme-valve-calcification-in-tavi-might-compromise-technical-success/" title="Read more" >...</a>

Favorable Outcomes with New Generation Transcatheter Heart Valves in Bicuspids

Original Title: Bicuspid Aortic Valve Stenosis Favorable Early Outcomes UIT a Next-Generation Transcatheter Heart Valve in a Multicenter Study. Reference: Gidon Y. Perlman J Am Coll Cardiol Interv 2016;9:817-24 Courtesy of Dr. Carlos Fava. Congenital bicuspid aortic valves are infrequent and are associated with severe calcification in elderly patients. Transcatheter aortic valve replacement to treat bicuspid<a href="https://solaci.org/en/2016/04/27/favorable-outcomes-with-new-generation-transcatheter-heart-valves-in-bicuspids/" title="Read more" >...</a>

Transcatheter Tricuspid Valve in valve

Original Title: Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valve. An International, Multicenter Registry Study. Reference: Doff B. McElhinney, et al. Circulation 2016;133:1582-93 Courtesy of Dr. Carlos Fava. Transcatheter tricuspid valve in valve implantation (TVIV) is infrequent, complex and biological valves last from 10 to 15 years. Reoperation is associated with high<a href="https://solaci.org/en/2016/04/21/transcatheter-tricuspid-valve-in-valve/" title="Read more" >...</a>

The SAPIEN 3 Valve Resulted Superior to Surgery in an Observational Study

The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN 3 valve showed lower rates of death, stroke and paravalvular leak at one year than patients undergoing surgery. This third generation improves the SAPIEN XT with a skirt designed to prevent<a href="https://solaci.org/en/2016/04/08/the-sapien-3-valve-resulted-superior-to-surgery-in-an-observational-study/" title="Read more" >...</a>

CoreValve US Pivotal: at 3 Years, the Self-Expanding Valve Maintains Its Advantage vs. Surgery

At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery. These findings could suggest that the self-expanding valve should be considered the preferred treatment in patients with symptomatic severe aortic stenosis at increased risk for surgery. The study included 797 patients<a href="https://solaci.org/en/2016/04/08/corevalve-us-pivotal-at-3-years-the-self-expanding-valve-maintains-its-advantage-vs-surgery/" title="Read more" >...</a>

Less Paravalvular Regurgitation and More Pacemakers for the New Balloon Expandable Valve

Original Title: Changes in the Pacemaker Rate After Transition from Edwards SAPIEN XT to SAPIEN 3 Transcatheter Aortic Valve Implantation. The Critical Role of Valve Implantation Height. Reference: Fernando De Torres-Alba et al. J Am CollCardiolIntv. 2016, online before print.   The aim of this study was to analyze pacemaker implantation rates with the new generation<a href="https://solaci.org/en/2016/03/31/less-paravalvular-regurgitation-and-more-pacemakers-for-the-new-balloon-expandable-valve/" title="Read more" >...</a>

TAVR-LM Registry: Transcatheter Aortic Valve Replacement and Left Main Stenting

Original Title: Outcomes in Patients with Transcatheter Aortic Valve Replacement and Left Main Stenting. The TAVR-LM Registry. Reference: TarunChakravarty et al. Journal of the American College of Cardiology, Vol 67, N° 8, 2016. Courtesy of Dr. Santiago F. Coroleu. High surgical risk patients with severe aortic stenosis and significant left main aortic arterydiseaseare often treated combining<a href="https://solaci.org/en/2016/03/22/tavr-lm-registry-transcatheter-aortic-valve-replacement-and-left-main-stenting/" title="Read more" >...</a>